{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:53:20Z","timestamp":1762505600318},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T00:00:00Z","timestamp":1268697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Clin Pharmacol"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>New drugs are generally claimed to represent a therapeutic innovation. However, scientific evidence of a substantial clinical advantage is often lacking. This may be the result of using inadequate control groups or surrogate outcomes only in the clinical trials. In view of this, EVITA was developed as a user-friendly transparent tool for the early evaluation of the additional therapeutic value of a new drug.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>EVITA does not evaluate a new compound <jats:italic>per se<\/jats:italic> but in an approved indication in comparison with existing therapeutic strategies. Placebo as a comparator is accepted only in the absence of an established therapy or if employed in an <jats:italic>add-on<\/jats:italic> strategy on top. The evaluation attributes rating points to the drug in question, taking into consideration both therapeutic benefit and risk profile. The compound scores positive points for superiority in efficiency and\/or adverse effects as demonstrated in randomized controlled trials (RCTs), whilst negative points are awarded for inferiority and\/or an unfavorable risk profile. The evaluation follows an algorithm considering the clinical relevance of the outcomes, the strength of the therapeutic effect and the number of RCTs performed. Categories for therapeutic aim and disease severity, although essential parts of the EVITA assessment, are attributed but do not influence the EVITA score which is presented as a color-coded bar graph. In case the available data were unsuitable for an EVITA calculation, a traffic-type yield sign is assigned instead to criticize such practice. The results are presented online <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.evita-report.de\" ext-link-type=\"uri\">http:\/\/www.evita-report.de<\/jats:ext-link> together with all RCTs considered as well as the reasons for excluding a given RCT from the evaluation. This allows for immediate revision in response to justified criticism and simplifies the inclusion of new data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>As examples, four compounds which received approval within the last years were evaluated for one of their clinical indications: lenalidomide, pioglitazone, bupropion and zoledronic acid. Only the first achieved an EVITA score above zero indicating therapeutic advantage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The strength of EVITA appears to lie in its speedy assessment of the potential therapeutic advantage of a new drug for a given indication. At the same time, this approach draws attention to the typical deficits of data used for drug approval. EVITA is not intended to replace classical health technology assessment reports but rather serves as a screening tool in the sense of horizon scanning.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1472-6904-10-5","type":"journal-article","created":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T19:15:22Z","timestamp":1268766922000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["EVITA: a tool for the early EValuation of pharmaceutical Innovations with regard to Therapeutic Advantage"],"prefix":"10.1186","volume":"10","author":[{"given":"Isabel","family":"P\u00fcntmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Schmacke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Melander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"M\u00fchlbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,16]]},"reference":[{"key":"86_CR1","volume-title":"Wissenschaftliche Verlagsgesellschaft mbH Stuttgart","author":"U Fricke","year":"2008","unstructured":"Fricke U, Klaus W: Neue Arzneimittel - Fakten und Bewertungen von 2004 bis 2006 zugelassenen Arzneimitteln. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart. 2008"},{"key":"86_CR2","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.drudis.2006.09.009","volume":"11","author":"L Caprino","year":"2006","unstructured":"Caprino L, Russo P: Developing a paradigm of drug innovation: an evaluation algorithm. Drug Discov Today. 2006, 11: 999-1006. 10.1016\/j.drudis.2006.09.009.","journal-title":"Drug Discov Today"},{"key":"86_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17: 1-12. 10.1016\/0197-2456(95)00134-4.","journal-title":"Control Clin Trials"},{"key":"86_CR4","first-page":"1","volume":"3.0","author":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health","year":"2006","unstructured":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Cancer Therapy Evaluation Program. 2006, 3.0: 1-71.","journal-title":"Cancer Therapy Evaluation Program"},{"key":"86_CR5","first-page":"0","volume":"2C","author":"European Commission - Enterprise and Industry Directorate-General - Pharmaceuticals","year":"2005","unstructured":"European Commission - Enterprise and Industry Directorate-General - Pharmaceuticals: A guideline on Summary of Product Characteristics. The Rules Governing Medicinal Products in the European Union. 2005, 2C: 0-25. [http:\/\/ec.europa.eu\/enterprise\/pharmaceuticals\/eudralex\/vol-2\/c\/spcguidrev1-oct2005.pdf]","journal-title":"The Rules Governing Medicinal Products in the European Union"},{"key":"86_CR6","first-page":"1","volume-title":"Fachinformation (Summary of Product Characteristics) - Rote Liste Service GmbH Berlin","author":"Celgene","year":"2007","unstructured":"Celgene: Revlimid\u00ae Hartkapseln. Fachinformation (Summary of Product Characteristics) - Rote Liste Service GmbH Berlin. 2007, 1-8. Access via password, [http:\/\/www.fachinfo.de]"},{"key":"86_CR7","first-page":"1","volume-title":"European Public Assessment Report","author":"European Medicines Agency","year":"2007","unstructured":"European Medicines Agency: Revlimid\u00ae - Scientific Discussion. European Public Assessment Report. 2007, 1-42. [http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/revlimid\/H-717-en6.pdf]"},{"key":"86_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1365-2141.2005.05867.x","volume":"132","author":"A Smith","year":"2005","unstructured":"Smith A, Wisloff F, Samson D, UK Myeloma Forum, Nordic Myeloma Study Group, British Committee for Standards in Haematology: Guidelines on the diagnosis and management of multiple myeloma. British Journal of Haematology. 2005, 132: 410-451. 10.1111\/j.1365-2141.2005.05867.x. [http:\/\/www.bcshguidelines.com\/pdf\/multiplemyeloma0206.pdf]","journal-title":"British Journal of Haematology"},{"key":"86_CR9","volume-title":"Kompetenznetz online","author":"German-Speaking Myeloma Multicenter Group (GMMG), Deutsche Studiengruppe Multiples Myelom (DSMM)","year":"2008","unstructured":"German-Speaking Myeloma Multicenter Group (GMMG), Deutsche Studiengruppe Multiples Myelom (DSMM): Kompetenznetz Maligne Lymphome. Kompetenznetz online. 2008, [http:\/\/www.lymphome.de\/InfoLymphome\/MultipleMyelome\/]"},{"key":"86_CR10","volume-title":"AWMF online","author":"T Prietzel","year":"2003","unstructured":"Prietzel T, P\u00f6tsch W, von Salis-Soglio G, Deutsche Gesellschaft f\u00fcr Orthop\u00e4die und Orthop\u00e4dische Chirurgie (DGOOC), Berufsverband der \u00c4rzte f\u00fcr Orthop\u00e4die (BVO): Solit\u00e4res und multiples Myelom (S1-Leitlinie). AWMF online. 2003"},{"key":"86_CR11","first-page":"1","volume-title":"Leitlinien der Deutschen Gesellschaft f\u00fcr H\u00e4matologie und Onkologie","author":"P Liebisch","year":"2007","unstructured":"Liebisch P, Peest D, Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Onkologie (DGHO): Multiples Myelom. Leitlinien der Deutschen Gesellschaft f\u00fcr H\u00e4matologie und Onkologie. 2007, 1-11."},{"key":"86_CR12","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007, 357: 2123-2132. 10.1056\/NEJMoa070594.","journal-title":"N Engl J Med"},{"key":"86_CR13","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007, 357: 2133-2142. 10.1056\/NEJMoa070596.","journal-title":"N Engl J Med"},{"key":"86_CR14","first-page":"1","volume-title":"Fachinformation (Summary of Product Characteristics) - Rote Liste Service GmbH Berlin","author":"Takeda Pharma","year":"2007","unstructured":"Takeda Pharma: Actos (TM) Tabletten. Fachinformation (Summary of Product Characteristics) - Rote Liste Service GmbH Berlin. 2007, 1-5. Access via password, [http:\/\/www.fachinfo.de]"},{"key":"86_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lef\u00e8bvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Kor\u00e1nyi L, Laakso M, Mok\u00e1n M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005, 366: 1279-1289. 10.1016\/S0140-6736(05)67528-9.","journal-title":"Lancet"},{"key":"86_CR16","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/S0149-2918(00)83039-8","volume":"22","author":"D Einhorn","year":"2000","unstructured":"Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000, 22: 1395-1409. 10.1016\/S0149-2918(00)83039-8.","journal-title":"Clin Ther"},{"key":"86_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0002-9343(01)00713-6","volume":"111","author":"MS Kipnes","year":"2001","unstructured":"Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001, 111: 10-17. 10.1016\/S0002-9343(01)00713-6.","journal-title":"Am J Med"},{"key":"86_CR18","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2337\/diacare.27.7.1647","volume":"27","author":"B Charbonnel","year":"2004","unstructured":"Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A: The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004, 27: 1647-1653. 10.2337\/diacare.27.7.1647.","journal-title":"Diabetes Care"},{"key":"86_CR19","first-page":"1","volume-title":"Fachinformation (Summary of Product Characteristics) - Rote Liste Service GmbH Berlin","author":"GlaxoSmithKline","year":"2007","unstructured":"GlaxoSmithKline: Elontril\u00ae 150 mg\/300 mg. Fachinformation (Summary of Product Characteristics) - Rote Liste Service GmbH Berlin. 2007, 1-6. Access via password, [http:\/\/www.fachinfo.de]"},{"key":"86_CR20","first-page":"1","volume-title":"Fachinformation (Summary of Product Characteristics) - Rote Liste Service GmbH Berlin","author":"GlaxoSmithKline","year":"2008","unstructured":"GlaxoSmithKline: Zyban\u00ae 150 mg Retardtabletten. Fachinformation (Summary of Product Characteristics) - Rote Liste Service GmbH Berlin. 2008, 1-6. Access via password, [http:\/\/www.fachinfo.de]"},{"key":"86_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0006-3223(01)01317-8","volume":"51","author":"KL Weihs","year":"2002","unstructured":"Weihs KL, Houser TL, Batey SR, Ascher JA, Bolden-Watson C, Donahue RM, Metz A: Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry. 2002, 51: 753-761. 10.1016\/S0006-3223(01)01317-8.","journal-title":"Biol Psychiatry"},{"key":"86_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.4088\/JCP.v67n0602","volume":"67","author":"JW Jefferson","year":"2006","unstructured":"Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, Wightman DS, Modell JG: Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006, 67: 865-873. 10.4088\/JCP.v67n0602.","journal-title":"J Clin Psychiatry"},{"key":"86_CR23","first-page":"1","volume-title":"online GSK clinical trial register","author":"GlaxoSmithKline","year":"2006","unstructured":"GlaxoSmithKline: AK130940 - A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-release Bupropion Hydrochloride (150 mg-300 mg once daily) in Elderly Subjects with Major Depressive Disorder. online GSK clinical trial register. 2006, 1-7. [http:\/\/www.gsk-clinicalstudyregister.com\/]"},{"key":"86_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4088\/JCP.v61n0309","volume":"61","author":"KL Weihs","year":"2000","unstructured":"Weihs KL, Settle EC, Batey SR, Houser TL, Donahue RM, Ascher JA: Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry. 2000, 61: 196-202.","journal-title":"J Clin Psychiatry"},{"key":"86_CR25","first-page":"1","volume-title":"online GSK clinical trial register","author":"GlaxoSmithKline","year":"2006","unstructured":"GlaxoSmithKline: WXL101497 - A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150 mg - 300 mg once daily), Extended-Release Venlafaxine Hydrochloride (75 mg - 150 mg once daily) and Placebo in Subjects with Major Depressive Disorder. online GSK clinical trial register. 2006, 1-8. [http:\/\/www.gsk-clinicalstudyregister.com\/]"},{"key":"86_CR26","first-page":"1","volume-title":"online GSK clinical trial register","author":"GlaxoSmithKline","year":"2006","unstructured":"GlaxoSmithKline: AK130939 - A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150 mg - 300 mg once daily), Extended-Release Venlafaxine Hydrochloride (75 mg - 150 mg once daily) and Placebo in Subjects with Major Depressive Disorder. online GSK clinical trial register. 2006, 1-7. [http:\/\/www.gsk-clinicalstudyregister.com\/]"},{"key":"86_CR27","first-page":"1","volume-title":"Fachinformation (Summary of Product Characteristics) - Rote Liste Service GmbH Berlin","author":"Novartis Pharma","year":"2008","unstructured":"Novartis Pharma: Aclasta\u00ae 5 mg Infusionsl\u00f6sung. Fachinformation (Summary of Product Characteristics) - Rote Liste Service GmbH Berlin. 2008, 1-6. Access via password, [http:\/\/www.fachinfo.de]"},{"key":"86_CR28","first-page":"1","volume":"H-595-PI","author":"Novartis Pharma GmbH","year":"2008","unstructured":"Novartis Pharma GmbH: Anhang 1 - Zusammenfassung der Merkmale des Arzneimittels (Aclasta 5 mg Infustionsl\u00f6sung). EMEA EPAR Produktinformation. 2008, H-595-PI: 1-30. [http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/aclasta\/emea-combined-h595de.pdf]","journal-title":"EMEA EPAR Produktinformation"},{"key":"86_CR29","first-page":"1","volume-title":"Fachinformation (Summary of Product Characteristics) - Rote Liste Service GmbH Berlin","author":"Novartis Pharma","year":"2008","unstructured":"Novartis Pharma: Zometa\u00ae 4 mg\/5 ml. Fachinformation (Summary of Product Characteristics) - Rote Liste Service GmbH Berlin. 2008, 1-7. Access via password, [http:\/\/www.fachinfo.de]"},{"key":"86_CR30","first-page":"1","volume-title":"European Public Assessment Report","author":"European Medicines Agency","year":"2005","unstructured":"European Medicines Agency: Aclasta\u00ae - Scientific Discussion. European Public Assessment Report. 2005, 1-24. [http:\/\/www.ema.europa.eu\/humandocs\/Humans\/EPAR\/aclasta\/aclasta.htm]"},{"key":"86_CR31","first-page":"1","volume-title":"European Public Assessment Report","author":"European Medicines Agency","year":"2007","unstructured":"European Medicines Agency: Aclasta\u00ae - Scientific Discussion - Procedure number: EMEA-H-595-II-10-AR. European Public Assessment Report. 2007, 1-37. [http:\/\/www.ema.europa.eu\/humandocs\/Humans\/EPAR\/aclasta\/aclasta.htm]"},{"key":"86_CR32","first-page":"1","volume-title":"European Public Assessment Report","author":"European Medicines Agency","year":"2008","unstructured":"European Medicines Agency: Assessment Report Aclasta\u00ae - (INN: zoledronic acid) - Aclasta H-535-II-10-AR Scientific Discussion. European Public Assessment Report. 2008, 1-60. [http:\/\/www.ema.europa.eu\/humandocs\/Humans\/EPAR\/aclasta\/aclasta.htm]"},{"key":"86_CR33","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002, 346: 653-661. 10.1056\/NEJMoa011807.","journal-title":"N Engl J Med"},{"key":"86_CR34","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007, 356: 1809-1822. 10.1056\/NEJMoa067312.","journal-title":"N Engl J Med"},{"key":"86_CR35","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/0002-9149(91)90308-8","volume":"68","author":"T Akiyama","year":"1991","unstructured":"Akiyama T, Pawitan Y, Greenberg H, Kuo CS, Reynolds-Haertle RA: Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol. 1991, 68: 1551-1555. 10.1016\/0002-9149(91)90308-8.","journal-title":"Am J Cardiol"},{"key":"86_CR36","first-page":"305","volume":"27","author":"AJ Scheen","year":"2001","unstructured":"Scheen AJ: Thiazolidinediones and liver toxicity. Diabetes Metab. 2001, 27: 305-313.","journal-title":"Diabetes Metab"},{"key":"86_CR37","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"GL Anderson","year":"2004","unstructured":"Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004, 291: 1701-1712. 10.1001\/jama.291.14.1701.","journal-title":"JAMA"},{"key":"86_CR38","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1001\/jama.295.14.1647","volume":"295","author":"ML Stefanick","year":"2006","unstructured":"Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT: Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006, 295: 1647-1657. 10.1001\/jama.295.14.1647.","journal-title":"JAMA"},{"key":"86_CR39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1517\/14740338.6.4.397","volume":"6","author":"L Testa","year":"2007","unstructured":"Testa L, Bhindi R, Agostoni P, Abbate A, Zoccai GG, van Gaal WJ: The direct thrombin inhibitor ximelagatran\/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin Drug Saf. 2007, 6: 397-406. 10.1517\/14740338.6.4.397.","journal-title":"Expert Opin Drug Saf"}],"container-title":["BMC Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-10-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6904-10-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-10-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-10-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T11:17:01Z","timestamp":1630495021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/1472-6904-10-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,16]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["86"],"URL":"https:\/\/doi.org\/10.1186\/1472-6904-10-5","relation":{},"ISSN":["1472-6904"],"issn-type":[{"value":"1472-6904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,16]]},"assertion":[{"value":"8 April 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"5"}}